BioWorld

June 18, 2008

Genzyme Seeks Mozobil Nod in Lymphoma, Multiple Myeloma

Cambridge, Mass.-based Genzyme Corp. submitted marketing applications in the U.S and Europe for its lymphoma and multiple myeloma treatment Mozobil (plerixafor), a small-molecule CXCR4 chemokine receptor antagonist. (BioWorld Today) Read More

$30M Fund Would Aid Aussie Academics, Spur Spinouts

U.S. Biosimilar Debate Crucial to Worldwide Biotech Industry

India: Moving from Services to Sustainable Innovation

Elan Rises on Phase II Data in Alzheimer's Disease

Japanese Partnerships Offer Opportunities, Challenges

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 8, 2026.

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...